Tuomilehto J. Relationship of socioeconomic status to the incidence and prehospital, 28 day, and 1-year mortality rates of acute coronary events in the FINMONICA myocardial infarction register study. Dear Sir, Extracellular adenine nucleotides regulate a broad range of physiological cellular responses through G-protein-coupled P2Y receptors and ligand-gated P2X ion channels, operating on different scales of time and distances (1). Platelet P2 receptors have been identified to consist of three representatives, namely P2Y 1 , P2Y 12 , and P2X 1 (2).
Light transmission recordings in hirudinized PRP containing 1U/ml apyrase. Platelet shape change was induced by 0.5 M HPLC-purified ␣,␤-meATP (A) or 1 M HPLC-purified ADP (B), in the presence of increasing concentrations of A2P5P, as indicated. Arrows show the time of addition of agonists. Percentage light transmission as well as time bars are specified. The curves are representative of at least 3 independent experiments performed on different individuals. Aggregation is prevented by the simultaneous presence of the neutralizing monoclonal anti-GPIIb/IIIa antibody MA-16N7C2 (50 g/ml) (11) C. Averaged peak currents measured in P2X 1 -expressing Xenopus oocytes stimulated with 100 M ␣,␤-meATP (n = 13) alone or in the presence of 400 M A2P5P (n = 11). Data are represented as the mean ± SEM and are expressed as percentage of the peak current induced by ␣,␤-meATP within the same batch of oocytes (*: p< 0.05) view of ATP in haemostasis has been questioned. Recent findings indeed indicate that P2X 1 mediates reversible platelet shape change (4), but also is involved in platelet shape change and aggregation induced by collagen (5) . The concept of P2 receptor activation in human platelets would thus rely both on ATP-mediated fast signaling through the P2X 1 channel, and on ADP activation of the P2Y 1 and P2Y 12 receptors.
Pharmacological classification of P2Y and P2X receptors and unambigous definition of their physiological roles have long been problematic due to lack of selective receptor antagonists. Although selective antagonists now exist that discriminate between P2Y 1 and P2Y 12 , selective blockade of platelet P2X 1 is still complicated. Notably, the P2Y 1 antagonist, N 6 -methyl-2'-deoxyadenosine-3',5'-biphosphate (MRS 2179) (6), acting as an antiplatelet agent, has also been reported to be an antagonist of P2X 1 in vitro (7) . The adenine nucleotide derivatives, adenosine 3'-phosphate 5'-phosphosulfate (A3P5PS), adenosine 3', 5'-diphosphate (A3P5P), and adenosine 2', 5'-diphosphate (A2P5P) are competitive antagonists at the human P2Y 1 receptor stably expressed in 1321N1 astrocytoma cells (8) . Because these compounds are inactive at Gi protein-coupled P2Y receptors, they are widely used for the analysis of the Gq protein-coupled P2Y 1 receptor function in platelet activation without affecting P2Y 12 (2) . For instance, the involvement of P2Y 1 in the initiation of platelet aggregation elicited by low concentrations of U46619 or thrombin, known to depend on ADP release, has been demonstrated through the inhibitory effect of A2P5P (9) . However, whether these molecules affect the platelet P2X 1 receptor function is unknown.
We have investigated the effect of A2P5P on the quickly reversible platelet shape change induced by the selective P2X 1 agonist, ␣,␤-methylene adenosine 5'-triphosphate (␣,␤-meATP). It appeared that a 1 min-pre-incubation of the platelets with A2P5P dose-dependently inhibited platelet shape change evoked by 0.5 M ␣,␤-meATP, inhibition being almost complete at 400 M A2P5P (Fig. 1A) . This concentration of A2P5P fully prevents the ADP-induced platelet shape change through P2Y 1 (Fig. 1B) . Accordingly, upon heterologous expression of P2X 1 in Xenopus oocytes (10), 400 M A2P5P could reduce the peak amplitude current evoked by 100 M ␣,␤-meATP to 35,74 ± 14 % (p = 0.019) of its initial value (mean peak currents = 0.805 ± 0.162 A, n = 13 versus 0.2877 ± 0.1129 A, n = 11 in the presence of A2P5P) (Fig. 1C) . These data thus indicate that the P2Y 1 antagonist A2P5P, previously described to be specific, exhibits non-selective antagonism at recombinant and human platelet P2X 1 receptors.
The non-selective inhibitory effect of A2P5P on P2X 1 activity has probably hampered correct evaluation of the contribution of the P2X 1 ion channel to platelet activation by many authors. This phenomenon, added to the difficulties to preserve fast-desensitizing P2X 1 responses during platelet preparation, may partly explain why these authors have often considered the role of this receptor in platelets to be elusive. 
